Thomson Reuters Foundation

Inform - Connect - Empower

Vaccines group seeks $7.5 bln to protect 300 million children

Source: Reuters - Tue, 20 May 2014 14:28 GMT
Author: Reuters
hum-peo hum-dis
In this 2012 file photo a woman rests her head against the bed where her 21-month-old daughter suffering from malaria and diarrhoea rests at the Princess Marie Louise Children's Hospital in Accra, Ghana. REUTERS/GAVI/Olivier Asselin/Handout
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

* Money would fund GAVI's programmes from 2016 to 2020

* GAVI works with drugmakers to cut vaccine costs for poor

* 1.5 mln children a year die of vaccine-preventable disease (Updates with pledge from European Union, price freeze from GSK)

By Kate Kelland

LONDON, May 20 (Reuters) - The GAVI global vaccines alliance appealed on Tuesday for $7.5 billion to help immunize another 300 million children against life-threatening diseases between 2016 and 2020 and save up to 6 million more lives.

GAVI said the additional investments, which it hopes to get mainly from global health philanthropists and the governments of developed nations, could double the number of lives saved through GAVI-supported vaccines to an estimated 12 million.

"We are faced with an historic opportunity to support countries to build sustainable immunisation programmes that will protect entire generations of children," the group's chairman, Dagfinn Hoybraten, said in a statement.

"The investments we all make now can ensure the equivalent of two children every second will be reached with GAVI-supported vaccines for five years and secure the future health and economic prosperity of all our children in years to come."

GAVI, which is backed by the Bill & Melinda Gates Foundation, the World Health Organisation (WHO), the World Bank, UNICEF, donor governments and others, funds immunisation programmes for nations that cannot afford standard prices.

The group targets common but deadly diseases such as pneumonia, diarrhoea and cervical cancer and says it has already saved around 6 million lives since its launch in 2000.

Seth Berkley, GAVI's chief executive, told Reuters the alliance's target of an extra $7.5 billion would be added to $2 billion already in hand for 2016-2020.

This is around 15 percent more than GAVI has for the current five-year period, he said, and is necessary because around 1.5 million children die each year of vaccine-preventable diseases.

The European Union announced in response on Tuesday that it would pledge 175 million euros ($240 million) in funding for the alliance for 2014-2020.

Berkley said such programmes would produce gains worth $80 billion to $100 billion, by cutting the cost of treating illness and by keeping people well and productive into adulthood.

GAVI uses its private and government donors' backing to negotiate with pharmaceutical firms such as GlaxoSmithKline , Merck and Pfizer to bring down vaccine prices for the poor. It then works with partners to bulk-buy and deliver vaccines to countries whose populations need them most.

The group says its influence on the vaccines market so far has led to a 37 percent decrease in the cost for a GAVI-eligible country to vaccinate a child with pentavalent, pneumococcal and rotavirus vaccines since 2010.

GSK, which sells several of its vaccines - including rotavirus, pneumococcal disease and cervical cancer shots - at reduced prices through GAVI to poor countries, said on Tuesday it would continue to freeze those prices for a further five years for countries who "graduate" from GAVI support.

By 2020, 22 countries with growing economies will become too wealthy to be eligible for GAVI's help, allowing GAVI to focus on the poorest countries and give developing economy governments responsibility for immunisation. ($1 = 0.7289 Euros) (Editing by Ruth Pitchford)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs